Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-11-29
2005-11-29
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S183000
Reexamination Certificate
active
06969717
ABSTRACT:
The present invention provides compounds of formula I,and pharmaceutically acceptable salts thereof.The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
REFERENCES:
patent: 2003/0069244 (2003-04-01), Leftheris et al.
patent: WO0071129 (2000-11-01), None
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition,vol. 1, 1004-1010, 1996.
Wolft Manfred E. “Burger's Medicinal Chemistry, 5ed, Part 1”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutices, 3ed.”, Marcel Dekker, New York. 1996, pp. 451 and 596.
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Fan et al., Trend Pharmacol. Sci., vol. 16, pp. 57-66 (1995).
Folkman, Nature Medicine, vol. 1, pp. 27-31 (1995).
Cullinan-Bove et al., Endocrinology, vol. 133, pp. 829-837 (1993).
Senger et al., Cancer and Metastasis Reviews, vol. 12, pp. 303-324 (1993).
DeVries et al., Science, vol. 255, pp. 989-991 (1992).
Terman et al., Biochem. Biophys. Res. Comm., vol. 187, pp. 1579-1586 (1992).
Jakeman et al., Endocrinology, vol. 133, pp. 848-859 (1993).
Kolch et al., Breast Cancer Research and Treatment, vol. 36, pp. 139-155 (1995).
Connolly et al., J. Biol. Chem., vol. 264, pp. 20017-20024 (1989).
U.S. Appl. No. 10/289,010, filed Nov. 6, 2002, Pending.
U.S. Appl. No. 09/573,829, filed May 18, 2000, Pending.
U.S. Appl. No. 10/294,281, filed Nov. 14, 2002, Pending.
U.S. Appl. No. 10/633,997, filed Aug. 4, 2003, Pending.
U.S. Appl. No. 10/623,171, filed Jul. 18, 2003, Pending.
U.S. Appl. No. 10/420,399, filed Apr. 22, 2003, Pending.
U.S. Appl. No. 10/420,445, filed Apr. 22, 2003, Pending.
U.S. Appl. No. 10/440,864, filed May 19, 2003, Pending.
Bhide Rajeev S.
L'Heureux Alexandre
Ruel Rejean
Thibault Carl
Balasubramanian Venkataraman
Bristol--Myers Squibb Company
Korsen Elliott
LandOfFree
Azaindole kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Azaindole kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Azaindole kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3500917